- Reaction score
- 13,396
- Points
- 1,360
What about moustaches?The long-term effects of haircuts are reasonably well known.
What about moustaches?The long-term effects of haircuts are reasonably well known.
And it appears that so are the long term effects of not being vaccinated, some travel restrictions, employment restrictions, ...hey, just like not getting that haircut.The long-term effects of haircuts are reasonably well known.
What about moustaches?
You didn't
And it appears that so are the long term effects of not being vaccinated, some travel restrictions, employment restrictions, ...hey, just like not getting that haircut.
Or BigpoxI'm sure glad I don't have smallpox...
You know what, that's fair.
Currently 2 provinces are doing vaccine passports, and one of those, Quebec, has said they won't be a used as a requirement for employment.
The Feds (Trudeau) have come out against it.( in a domestic sense)
So the only ones making inane arguments for some sort of societal restrictions based on vaccine status are people like you.
dapaterson said:
You already require proof of certain vaccinations for travel to certain countries. Some professions require proof of TB testing and, if there's a false positive, a chest xray.
Requiring proof of vaccination is nothing new... but thanks for reminding me. I have money to invest, and Alcan looks pretty good.
For international travel, sure.
For going to a restaurant, bar, sporting event? No.
One cannot argue the requirements other countries have in place for entry.Whatever you say.
How about Monkeypox?Or Bigpox
Fair enough.One cannot argue the requirements other countries have in place for entry.
One can argue what domestic requirements are for certain activities.
I don't bother with the former, and have had a consistent view on the latter.
2 doses of Pfizer's shot was 88% effective at preventing symptomatic disease from the Delta variant, compared to 93.7% against the Alpha variant, broadly the same as previously reported.
Two shots of AstraZeneca vaccine were 67% effective against the Delta variant, up from 60% originally reported, and 74.5% effective against the Alpha variant, compared to an original estimate of 66% effectiveness.
And:
"CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses."